⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JAZZ News
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
prnewswire.com
JAZZ
Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer
businesswire.com
JAZZ
EXEL
ABT
NCUX
CUR
SUTB
The Toy Insider™ Experts Share Top Shopping Tips to Find & Save Big on the Hottest Toys, Games & Gifts
prnewswire.com
7974.T
TOYS
BFAM
JAZZ
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
prnewswire.com
JAZZ
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
prnewswire.com
JAZZ
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
prnewswire.com
JAZZ
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance USA - English USA - English
prnewswire.com
JAZZ
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance USA - English USA - English
prnewswire.com
JAZZ
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
prnewswire.com
JAZZ
JAZZ
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
prnewswire.com
JAZZ
JAZZ